Nektar Therapeutics (NASDAQ:NKTR) Shares Bought by Barclays PLC

Barclays PLC grew its stake in Nektar Therapeutics (NASDAQ:NKTR) by 96.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 358,294 shares of the biopharmaceutical company’s stock after purchasing an additional 175,596 shares during the period. Barclays PLC owned approximately 0.19% of Nektar Therapeutics worth $466,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NKTR. Samlyn Capital LLC purchased a new position in Nektar Therapeutics in the 2nd quarter valued at $11,728,000. Eventide Asset Management LLC boosted its holdings in shares of Nektar Therapeutics by 24.8% in the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after acquiring an additional 1,870,904 shares in the last quarter. Millennium Management LLC increased its stake in shares of Nektar Therapeutics by 56.1% during the second quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock worth $5,778,000 after acquiring an additional 1,674,924 shares during the period. Nantahala Capital Management LLC raised its holdings in Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after purchasing an additional 1,634,046 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in Nektar Therapeutics during the second quarter worth about $1,037,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NKTR. BTIG Research reiterated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler initiated coverage on Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective on the stock. Finally, HC Wainwright assumed coverage on Nektar Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $6.50 target price for the company. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.10.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $0.96 on Friday. The business has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.21. The company has a market capitalization of $177.26 million, a P/E ratio of -1.14 and a beta of 0.57. Nektar Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.93.

Insider Buying and Selling at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 46,995 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now owns 1,195,710 shares of the company’s stock, valued at approximately $1,207,667.10. This represents a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the sale, the insider now owns 351,892 shares in the company, valued at $316,702.80. This trade represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 155,575 shares of company stock valued at $149,878. Insiders own 3.71% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.